What Is DHT

Dihydrotestosterone (DHT) is a potent androgen hormone produced when the enzyme 5-alpha reductase converts testosterone in tissues such as the prostate, skin, and hair follicles. It binds androgen receptors with substantially greater affinity than testosterone, making it the dominant androgen in certain peripheral tissues. DHT is essential for male sexual development during fetal life and puberty, yet in adulthood it is also implicated in hair loss and prostate growth.

DHT sits at the intersection of two major concerns in male aging: prostate health and hair preservation. As men age, the prostate continues to be exposed to DHT, and cumulative androgenic stimulation contributes to benign prostatic hyperplasia, a condition that affects a large fraction of men over fifty. Simultaneously, DHT-mediated miniaturization of hair follicles on the scalp drives androgenetic alopecia, which is the most common form of hair loss in men.

Beyond cosmetic and urological considerations, DHT influences body composition, libido, and neurosteroid production. It contributes to sexual function in ways that are distinct from testosterone itself, and some research suggests DHT-derived neurosteroids play roles in mood regulation. Understanding DHT metabolism is therefore relevant not just for managing specific symptoms, but for interpreting the broader landscape of androgen balance throughout the lifespan.

The conversion of testosterone to DHT occurs primarily through two isoforms of the enzyme 5-alpha reductase. Type 1 is found mainly in the skin, liver, and sebaceous glands, while Type 2 is concentrated in the prostate, seminal vesicles, epididymis, and hair follicles. When testosterone enters a cell expressing 5-alpha reductase, the enzyme removes a double bond from the steroid's A-ring, yielding DHT. This structural change increases the hormone's binding affinity for the androgen receptor by roughly three to five times compared to testosterone.

Once DHT binds the androgen receptor, the complex translocates to the cell nucleus and modulates gene transcription. In prostate epithelial cells, this drives proliferation and secretory activity. In susceptible scalp follicles, chronic DHT signaling shortens the anagen (growth) phase and progressively shrinks the follicle, producing thinner and shorter hairs until the follicle can no longer produce visible hair. The same mechanism has the opposite effect on body and facial hair, where DHT stimulates thicker growth.

DHT is metabolized primarily in the liver and excreted through the kidneys. The metabolites 3-alpha androstanediol glucuronide and androsterone are sometimes measured as indirect markers of peripheral DHT activity. Importantly, circulating serum DHT represents only a fraction of total DHT exposure, because much of the conversion and action occurs locally within target tissues. This is why two men with identical serum DHT levels can have very different clinical presentations depending on local enzyme activity and androgen receptor sensitivity.

DHT does not exist in isolation; it is one node in a tightly interconnected androgen network. Testosterone, produced primarily in the Leydig cells of the testes under the influence of luteinizing hormone (LH), serves as the precursor. Only about 5 to 10 percent of circulating testosterone undergoes conversion to DHT, but this small fraction exerts outsized effects in tissues rich in 5-alpha reductase. The remaining testosterone can also be aromatized to estradiol by the enzyme aromatase, meaning that testosterone, DHT, and estradiol exist in a dynamic equilibrium.

Sex hormone binding globulin (SHBG) adds another layer of regulation. SHBG binds DHT with higher affinity than it binds testosterone, so changes in SHBG levels alter the free (bioavailable) fractions of both hormones. Conditions that lower SHBG, such as obesity, insulin resistance, and hypothyroidism, tend to increase free androgen availability. Conversely, aging and liver disease can raise SHBG and reduce free DHT. This is why interpreting a DHT value without knowing SHBG, total testosterone, free testosterone, and estradiol gives an incomplete picture.

Testosterone replacement therapy introduces an important variable. Exogenous testosterone provides additional substrate for 5-alpha reductase, and men on TRT often see their DHT levels rise. Clinicians managing TRT need to monitor DHT alongside other androgens and estrogens to calibrate dosing and identify whether hair loss acceleration or prostate changes are occurring.

Excess DHT activity tends to manifest in specific target tissues rather than producing diffuse systemic symptoms. The scalp is often the first site where changes become visible: recession at the temples and thinning at the vertex follow a characteristic pattern described by the Norwood-Hamilton scale. Increased oiliness of the skin and persistent adult acne, particularly along the jawline and back, can also indicate heightened androgenic stimulation.

Urinary symptoms may point to DHT-mediated prostate enlargement. Weak stream, hesitancy, nocturia (frequent nighttime urination), and a sense of incomplete bladder emptying are hallmarks of benign prostatic hyperplasia. These symptoms develop gradually and are common enough to be dismissed as normal aging, but they warrant investigation because they can reflect a measurable hormonal driver.

Low DHT, whether from natural variation or pharmacological suppression, may present differently. Some men report decreased libido or genital sensation that is disproportionate to their testosterone levels. Mood changes, including flat affect or mild depressive symptoms, have been reported anecdotally in association with low DHT states, though establishing causation is difficult. Monitoring both symptoms and lab values over time provides the most useful clinical picture.

The most widely used pharmacological approach to reducing DHT is 5-alpha reductase inhibition. Finasteride (typically 1 mg daily for hair loss, 5 mg for prostate) selectively inhibits the Type 2 isoform and is FDA-approved for both indications. Dutasteride inhibits both Type 1 and Type 2 isoforms and produces a more complete reduction in serum DHT; it is approved for prostate hyperplasia in most markets and used off-label for hair loss. Topical formulations of finasteride and dutasteride are under investigation and may offer localized DHT reduction with less systemic exposure.

Non-pharmacological strategies include compounds with modest 5-alpha reductase inhibitory activity. Saw palmetto extract has been studied in multiple trials for prostate symptoms, with results ranging from slight benefit to no difference versus placebo. Pumpkin seed oil, green tea catechins, and certain isoflavones have shown in vitro inhibition of 5-alpha reductase, but clinical evidence supporting meaningful DHT reduction remains limited. Topical application of ketoconazole shampoo is sometimes used as an adjunct for scalp DHT reduction, though its primary mechanism is antifungal.

For men on testosterone replacement therapy who wish to limit DHT conversion, dose adjustment and delivery method selection can help. Transdermal testosterone (creams and gels) tends to produce higher DHT levels than injectable testosterone due to the high concentration of 5-alpha reductase in skin. Switching from topical to injectable forms, or reducing dose frequency, may lower DHT without adding a second medication. Any treatment decision should be grounded in repeated lab measurements and symptom tracking rather than a single data point.

The role of DHT in androgenetic alopecia and benign prostatic hyperplasia is well established through decades of clinical observation and large randomized controlled trials of 5-alpha reductase inhibitors. Finasteride and dutasteride have been studied extensively: finasteride inhibits primarily Type 2 5-alpha reductase and reduces serum DHT by approximately 70 percent, while dutasteride inhibits both isoforms and reduces DHT by over 90 percent. Clinical trials have demonstrated efficacy for both hair regrowth and prostate symptom relief, though the magnitude of benefit varies across individuals.

The safety profile of 5-alpha reductase inhibitors remains a subject of active investigation. Reports of persistent sexual side effects after discontinuation (sometimes termed post-finasteride syndrome) have prompted regulatory label updates and further study, though the prevalence, mechanism, and natural history of these effects are still debated. Separately, large chemoprevention trials examined whether long-term 5-alpha reductase inhibition could reduce prostate cancer incidence; results showed a reduction in low-grade tumors but a small increase in the detection of high-grade tumors, a finding whose interpretation (true biological effect versus detection bias) continues to be analyzed. Research into natural DHT modulation through compounds like saw palmetto, pumpkin seed oil, and certain polyphenols exists primarily at the level of small clinical trials and in vitro studies, with mixed and generally modest results.

Pharmacological suppression of DHT can produce sexual side effects including decreased libido, erectile dysfunction, and reduced ejaculate volume, though most users do not experience these. A small percentage of individuals report persistent symptoms after stopping 5-alpha reductase inhibitors, and the mechanisms behind this remain poorly understood. Excessive DHT suppression may also affect mood and cognitive function through reduced neurosteroid synthesis. Natural DHT-modulating supplements carry fewer documented risks but also have less robust evidence for efficacy. Any intervention that alters androgen metabolism should be guided by laboratory monitoring and clinical assessment rather than symptom-based self-treatment.